Collegium Pharmaceutical, Inc. (COLL)
| Market Cap | 872.73M |
| Revenue (ttm) | 321.23M |
| Net Income (ttm) | 41.96M |
| Shares Out | 34.95M |
| EPS (ttm) | 1.18 |
| PE Ratio | 21.35 |
| Forward PE | 7.13 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $25.15 |
| Previous Close | $24.76 |
| Change ($) | 0.39 |
| Change (%) | 1.58% |
| Day's Open | 24.76 |
| Day's Range | 24.62 - 25.43 |
| Day's Volume | 120,956 |
| 52-Week Range | 15.66 - 26.91 |
STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 202...
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today ...
The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.
STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today a...
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 –
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STOUGHTON, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 6,...
– 2020 First Full-Year of Profitability, Driven by Xtampza ® ER Revenue Growth and the Nucynta ® Acquisition –
STOUGHTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, Februar...
It's not every day that a company graduates to a slot in a high-profile stock index.
– Xtampza ® ER Revenues Expected in the Range of $155.0 million to $165.0 million –
Collegium Pharmaceutical recently reported their Q3 earnings with a beat on EPS and revenue. Despite some serious COVID-19 headwinds, Collegium was able to record another quarter of growth and increase ...
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q3 2020 Results - Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q3 2020 Results - Earnings Call Transcript
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 39.13% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.
STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, Novembe...
These three health-related businesses are well positioned to provide market-beating gains.
STOUGHTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today...
STOUGHTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, tod...
STOUGHTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, t...
STOUGHTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, tod...
Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2020 Results - Earnings Call Transcript
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -4.17% and 4.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
– Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020 –
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STOUGHTON, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, Augu...
Collegium Pharmaceuticals - Whether It's Too Cheap
AMRX vs. COLL: Which Stock Is the Better Value Option?
AMRX vs. COLL: Which Stock Is the Better Value Option?
These are the two healthcare stocks that possess the best value for the greatest reward in May.
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2020 Results - Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2020 Results - Earnings Call Transcript
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A company making abuse-deterrent opioids and that's barely listed in any nation-wide opioid litigation is becoming a rising star despite the prescription overdose crisis.
The Call On Collegium Pharmaceuticals
COLL vs. NBIX: Which Stock Is the Better Value Option?
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Collegium (COLL).
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2019 Results - Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2019 Results - Earnings Call Transcript
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625% conve...
Investors aren't happy about the drugmaker's proposed senior convertible note offering.
Collegium Pharmaceutical: 2020 Could Be A Great Year
STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced its intention to offer, subject to market and other conditions, $125,000,000 aggregate...
The speciality pharmaceutical company purchased the full rights to an important drug product.
Collegium Pharmaceutical Inc. (NASDAQ: COLL) shares popped on Friday after the firm announced that it will acquire the U.S. rights to the Nucynta franchise from Assertio Therapeutics.
– Financially Transformative Acquisition –
Prospects Appear Bright for Small Drug Industry in 2020
Collegium Pharmaceutical Is A Relatively Safe Opioid Pick For 2020
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest v...
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to C... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date May 7, 2015 |
| CEO Joseph Ciaffoni | Employees 234 |
| Stock Exchange NASDAQ | Ticker Symbol COLL |
Analyst Forecasts
According to 10 analysts, the average rating for COLL stock is "Buy." The 12-month stock price forecast is 29.57, which is an increase of 17.57% from the latest price.